Breast Cancer Stage
9
0
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
Screening For BCRL In Targeted Therapy For Breast Cancer
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer
Clinical Evaluation of Opto-Acoustic Image Quality With the Gen 2 Imagio System
The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study
COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer
Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer